{
    "nct_id": "NCT02944565",
    "official_title": "Daratumumab Infusion Acceleration",
    "inclusion_criteria": "* Patients must have received >= 2 daratumumab infusions and be scheduled to receive another dose\n* All races and ethnic groups are eligible for this study\n* Ability to understand and the willingness to sign a written informed consent document\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Any other medical condition, including mental illness or substance abuse, deemed by the principal investigator to likely interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results\n* Concurrent use of complementary or alternative medicines that in the opinion of the principal investigator would confound the interpretation of toxicities and/or antitumor activity of the study drug\n* Prisoner",
    "miscellaneous_criteria": ""
}